Georgia Medicare Bone Mass Measurement 2026 Guide

title: Georgia Medicare Bone Mass Measurement Guide subtitle: Section 1861(rr) of the Social Security Act, the Balanced Budget Act of 1997 (BBA) Section 4106 origin of the coverage, the National Coverage Determination NCD 150.3 Bone Mass Measurements, the 42 CFR 410.31 implementing regulations, the five qualifying eligibility categories, the every-two-years screening frequency with more-frequent coverage for specific clinical indications, the dual-energy X-ray absorptiometry (DXA) technology as gold standard, the other acceptable BMM modalities, the ACA Section 4104 preventive cost-sharing waiver application, the coordination with the IPPE and AWV preventive frameworks, the osteoporosis drug therapy pathway, the major Georgia bone health programs, and why bone mass measurement coverage matters for Georgia Medicare beneficiaries at fracture risk.

By Brevy Care Team · Last verified May 21, 2026

For every Georgia Medicare beneficiary asking whether their osteoporosis screening DXA scan is covered, every primary care provider ordering bone mass measurements during Annual Wellness Visits or routine preventive encounters in postmenopausal women, every gynecologist and endocrinologist managing patients with osteoporosis risk, every rheumatologist monitoring glucocorticoid-induced osteoporosis, every radiologist interpreting Georgia DXA scans, and every Georgia caregiver supporting a family member through fracture-prevention care, the Medicare Bone Mass Measurement benefit is a foundational coverage pathway that has been continuously available for more than two decades.

Section 1861(rr) of the Social Security Act, added by Section 4106 of the Balanced Budget Act of 1997, provides the statutory authority. National Coverage Determination 150.3 specifies the five qualifying categories: postmenopausal estrogen deficiency, vertebral abnormality suspicious for osteoporosis, long-term glucocorticoid therapy, primary hyperparathyroidism, and monitoring of FDA-approved osteoporosis drug therapy. Implementing regulations at 42 CFR 410.31 establish the every-two-years screening frequency and the more-frequent coverage for specific clinical indications.

This guide explains the federal statutory authorities, the five qualifying eligibility categories, the screening frequency, the acceptable BMM modalities (DXA, quantitative ultrasound, quantitative CT), DXA result interpretation, the coordination with the Initial Preventive Physical Examination and the Annual Wellness Visit, the coordination with osteoporosis drug therapy (bisphosphonates, denosumab, romosozumab, teriparatide, abaloparatide), the major Georgia bone health programs, and how Georgia Medicare beneficiaries access the BMM benefit.

The Federal Statutory Framework

Section 1861(rr) of the Social Security Act

Section 1861(rr) of the Social Security Act (codified at 42 U.S.C. 1395x(rr)) defines bone mass measurement and authorizes Medicare coverage for BMM tests in eligible beneficiaries. The statute:

• Defines "bone mass measurement" as a radiologic or radioisotopic procedure or other procedure for identifying bone mass or detecting bone loss
• Requires the procedure to be performed with equipment approved or cleared by the FDA
• Requires the procedure to be ordered by a treating physician
• Limits coverage to qualified individuals as determined by CMS

Section 1861(rr) was added to the Social Security Act by Section 4106 of the Balanced Budget Act of 1997.

Balanced Budget Act of 1997 (BBA)

The Balanced Budget Act of 1997 was the federal legislation that established Medicare coverage of bone mass measurements through Section 4106, which added Section 1861(rr) to the Social Security Act and authorized CMS to specify qualified individuals. The BBA was a comprehensive Medicare reform that also established the Medicare+Choice program (later renamed Medicare Advantage), the State Children's Health Insurance Program (SCHIP, now CHIP), and numerous other Medicare and Medicaid program changes.

National Coverage Determination NCD 150.3

CMS implemented Section 1861(rr) through National Coverage Determination NCD 150.3 Bone Mass Measurements, with subsequent updates. NCD 150.3 specifies:

• Five qualifying categories for BMM coverage
• Frequency limitations (every two years for screening, more frequent for specific clinical indications)
• Acceptable BMM modalities
• FDA equipment approval requirements
• Ordering physician requirements

NCD 150.3 has been periodically updated to reflect evolving evidence and FDA-approved BMM technologies; consult the current CMS Medicare Coverage Database entry for the latest text.

42 CFR 410.31 Implementing Regulations

Implementing regulations at 42 CFR 410.31 address bone mass measurements including:

• Qualified individuals definition
• Frequency limitations
• Conditions for coverage
• Documentation requirements

The regulation aligns with NCD 150.3 and provides the regulatory foundation for Medicare contractor claim adjudication.

ACA Section 4104 Preventive Services Cost-Sharing Waiver

Section 4104 of the Patient Protection and Affordable Care Act of 2010 eliminated Medicare beneficiary cost-sharing for certain preventive services. The cost-sharing waiver applies to preventive services rated A or B by the United States Preventive Services Task Force (USPSTF). For BMM, the cost-sharing waiver applies when:

• The beneficiary falls within the NCD 150.3 qualifying categories
• The BMM aligns with the current USPSTF Grade B osteoporosis screening recommendation

When both conditions are met, Medicare pays 100 percent of the approved amount; the beneficiary pays nothing. For BMM not aligned with USPSTF Grade B (for example, monitoring drug therapy in men, BMM in women not within the current USPSTF screening recommendation), standard Part B cost-sharing applies. Confirm the current USPSTF osteoporosis screening recommendation and its precise eligibility scope on the USPSTF website before counseling beneficiaries.

The Five Qualifying Bone Mass Measurement Categories

Category 1: Estrogen-Deficient Postmenopausal Woman at Clinical Risk

The first qualifying category covers women who are estrogen-deficient and at clinical risk for osteoporosis. Estrogen deficiency typically results from:

• Natural menopause
• Surgical menopause (oophorectomy)
• Premature ovarian insufficiency
• Chemotherapy-induced ovarian failure

Clinical risk factors that combine with estrogen deficiency include:

• Family history of osteoporosis or osteoporotic fracture
• Personal history of fragility fracture
• Low body weight
• Cigarette smoking
• Excessive alcohol consumption
• Sedentary lifestyle
• Caucasian or Asian ancestry
• Long-term medications that decrease bone density

This category captures the largest share of Medicare BMM screening, with postmenopausal women being the prototypical population for osteoporosis screening.

Category 2: Vertebral Abnormality on X-Ray

The second qualifying category covers individuals with vertebral abnormalities suggestive of osteoporosis, osteopenia, or vertebral fracture as demonstrated by X-ray imaging. Vertebral abnormalities may include:

• Loss of vertebral height
• Vertebral compression fracture
• Wedge deformity
• Biconcave deformity
• "Cod fish" vertebral appearance
• Other radiographic signs of bone loss

This category applies to both men and women. The vertebral abnormality serves as a marker of underlying bone health concern warranting BMM characterization.

Category 3: Long-Term Glucocorticoid Therapy

The third qualifying category covers individuals receiving (or expected to receive) long-term glucocorticoid (steroid) therapy at a clinically significant dose and duration, as specified in NCD 150.3. Glucocorticoid-induced osteoporosis (GIOP) is a well-recognized complication of chronic steroid therapy, with risks for both men and women. Refer to the current NCD 150.3 text for the precise duration and prednisone-equivalent dose thresholds.

Common chronic glucocorticoid indications include:

• Rheumatoid arthritis
• Polymyalgia rheumatica
• Systemic lupus erythematosus
• Inflammatory bowel disease (Crohn's, ulcerative colitis)
• Asthma and COPD (oral steroids)
• Vasculitides
• Other autoimmune and inflammatory conditions
• Solid organ or stem cell transplantation
• Chronic dermatologic conditions

For glucocorticoid-induced osteoporosis monitoring, BMM may be covered more frequently than every two years given the accelerated bone loss associated with chronic steroid therapy.

Category 4: Primary Hyperparathyroidism

The fourth qualifying category covers individuals with primary hyperparathyroidism. Primary hyperparathyroidism causes elevated parathyroid hormone (PTH) levels, which accelerate bone resorption and increase fracture risk. BMM is used to:

• Establish baseline bone density at diagnosis
• Monitor bone density changes during conservative management
• Inform surgical parathyroidectomy decision-making
• Monitor bone density recovery after parathyroidectomy

This category applies to both men and women diagnosed with primary hyperparathyroidism.

Category 5: Monitoring FDA-Approved Osteoporosis Drug Therapy

The fifth qualifying category covers individuals being monitored to assess response to or efficacy of FDA-approved osteoporosis drug therapy. Monitoring BMM:

• Establishes baseline before therapy initiation
• Confirms response to treatment (stabilization or improvement of BMD)
• Identifies inadequate response warranting therapy change
• Informs decision-making about therapy duration and drug holidays

For drug therapy monitoring, BMM may be covered annually or more frequently than every two years given the clinical utility of monitoring treatment response.

Bone Mass Measurement Screening Frequency

Every Two Years for Standard Screening

Medicare covers BMM every two years for screening of eligible beneficiaries. The two-year frequency:

• Reflects the rate at which clinically significant bone density changes typically occur
• Aligns with clinical practice guidelines
• Provides adequate monitoring without over-screening
• Supports cost-effective population screening

A beneficiary screened on June 15, 2026 would be eligible for the next covered screening on or after June 15, 2028. The clock counts from the date of the prior covered BMM.

More-Frequent Coverage for Specific Clinical Indications

Medicare covers BMM more frequently than every two years when medically necessary for specific clinical indications. NCD 150.3 specifies that more-frequent BMM is appropriate for:

• Monitoring response to FDA-approved osteoporosis drug therapy
• Monitoring high-dose glucocorticoid therapy effects on bone density
• Monitoring after fragility fracture
• Other clinically justified situations

The clinical indication and necessity must be documented to support more-frequent BMM under diagnostic coverage.

Frequency Tracking

Providers and beneficiaries should track:

• Last BMM date
• Whether the prior BMM was screening (every-two-years frequency) or monitoring (more frequent)
• Qualifying category and any change in eligibility
• Drug therapy status

EMR-based tracking supports systematic adherence to frequency rules.

Bone Mass Measurement Modalities

Dual-Energy X-Ray Absorptiometry (DXA)

Dual-energy X-ray absorptiometry (DXA) is the gold-standard BMM technology. DXA uses two low-energy X-ray beams to measure bone mineral density (BMD) at axial skeletal sites (hip, spine) and appendicular sites (forearm, heel).

DXA Advantages

• Low radiation exposure relative to most diagnostic imaging
• High precision and reproducibility across visits
• Well-validated against fracture risk
• Standardized T-score and Z-score reporting

DXA Procedure The patient lies supine on the DXA table; the X-ray scanner passes over the body imaging the lumbar spine and hip. The scan is non-invasive and painless and typically completes within a brief outpatient appointment. Patients should remove metal objects but otherwise require no preparation.

DXA Codes

• HCPCS 77080 (axial-skeleton DXA, hip and spine)
• HCPCS 77081 (appendicular-skeleton DXA, peripheral)

Refer to the current CMS HCPCS code descriptors and Palmetto GBA fee schedule for code definitions and Georgia-specific pricing.

Quantitative Ultrasound

Quantitative ultrasound (QUS) measures bone density at peripheral sites (typically the heel/calcaneus) using ultrasound. QUS:

• Uses no ionizing radiation
• Is portable (useful in screening settings)
• Has lower precision than DXA
• Provides screening rather than definitive diagnosis
• Cannot reliably monitor therapy response

QUS is reported under HCPCS 76977 (quantitative ultrasound bone density measurement, peripheral site). QUS is more commonly used in screening programs than in definitive diagnosis.

Quantitative CT (QCT)

Quantitative computed tomography (QCT) measures bone density using specialized CT scans, typically of the lumbar spine. QCT:

• Provides three-dimensional bone density measurement
• Can measure trabecular and cortical bone separately
• Has higher radiation exposure than DXA
• Has limited reference standards
• Is less commonly used than DXA

QCT is reported under HCPCS 77078 (quantitative CT bone density).

Modality Selection

DXA axial skeleton is the most commonly used Medicare BMM modality. DXA's combination of low radiation, high precision, low cost, and clinical validation makes it the standard. Peripheral DXA, QUS, and QCT are used in specific clinical contexts but represent smaller shares of Medicare BMM volume.

DXA Result Interpretation

T-Score Categories

DXA results are reported as T-scores, which are standard deviations from a young adult reference population. The World Health Organization (WHO) framework distinguishes normal, low bone mass (osteopenia), and osteoporosis using progressively lower T-score bands; severe (established) osteoporosis describes a beneficiary with osteoporotic-range bone density plus one or more fragility fractures. Consult current WHO and International Society for Clinical Densitometry (ISCD) guidance for the precise diagnostic thresholds.

Z-Score

Z-scores compare BMD to age-matched reference populations. Z-scores are particularly useful for:

• Pre-menopausal women
• Men under age 50
• Pediatric populations
• Evaluation of secondary causes of low bone density

A Z-score well below the age-matched mean is considered "below the expected range for age" and warrants evaluation for secondary causes.

Site-Specific Interpretation

DXA typically reports T-scores at:

• Lumbar spine (L1-L4 or L1-L3)
• Total proximal femur
• Femoral neck
• Distal radius (if obtained)

For postmenopausal women and men of qualifying age, the lowest T-score across the standard reporting sites drives the WHO categorization.

FRAX Fracture Risk Assessment

FRAX (Fracture Risk Assessment Tool) integrates DXA results with clinical risk factors to estimate 10-year probability of major osteoporotic fracture and hip fracture. FRAX informs:

• Treatment decisions in the osteopenia range
• Drug therapy initiation thresholds
• Treatment continuation decisions

FRAX is commonly used by clinicians to translate DXA results into individualized treatment recommendations.

ACA Section 4104 Cost-Sharing Coordination

Cost-Sharing Waived for USPSTF Grade B Aligned BMM

The ACA Section 4104 cost-sharing waiver applies to BMM when the beneficiary meets BOTH:

• An NCD 150.3 qualifying category (Category 1: estrogen-deficient postmenopausal woman; etc.)
• The current USPSTF Grade B osteoporosis screening recommendation

When both conditions are met, the Part B deductible is waived and the standard 20 percent coinsurance is waived. The beneficiary pays nothing for the covered BMM from an assignment-accepting provider.

Standard Cost-Sharing for Other Qualifying BMM

For BMM that qualifies under NCD 150.3 but does NOT align with the current USPSTF Grade B recommendation (for example, beneficiaries outside the USPSTF screening scope, glucocorticoid-induced osteoporosis monitoring in men, drug therapy monitoring in any population), standard Part B coverage applies:

• Part B deductible applies (if not already met)
• After deductible, 20 percent coinsurance of the Medicare-approved amount

Medicare Supplement (Medigap) plans typically cover the 20 percent coinsurance; Medicare Advantage plans cover per plan benefits.

Practical Implications

In Georgia practice, primary care providers ordering BMM for beneficiaries who fit the USPSTF Grade B screening recommendation benefit from the zero-cost-sharing structure under ACA Section 4104. For other indications, beneficiaries should understand that cost-sharing may apply.

Coordination With IPPE and AWV

Initial Preventive Physical Examination (IPPE)

The IPPE includes review of preventive services with referrals as appropriate. For beneficiaries in their first year of Medicare Part B enrollment, the IPPE provides an opportunity for the provider to discuss BMM and order it when NCD 150.3 eligibility is met.

Annual Wellness Visit (AWV)

The AWV personalized prevention plan incorporates BMM consideration:

• For postmenopausal women in the USPSTF-recommended screening window, routine BMM consideration if not done within the prior two years
• For women outside that window who carry elevated fracture risk, BMM consideration based on individualized risk assessment
• For men and women on long-term glucocorticoids, BMM monitoring consideration
• For beneficiaries on osteoporosis therapy, monitoring BMM consideration

The AWV serves as the recurring touchpoint for systematic BMM management throughout a beneficiary's Medicare tenure.

Osteoporosis Drug Therapy Coordination

Oral Bisphosphonates (Part D)

Oral bisphosphonates are first-line osteoporosis therapy for most patients:

• Alendronate (Fosamax, generic), weekly oral, widely available and low cost
• Risedronate (Actonel, generic), weekly or monthly oral
• Ibandronate (Boniva, generic), monthly oral or quarterly IV

Oral bisphosphonates are covered under Medicare Part D for beneficiaries enrolled in Part D plans. Generic alendronate is typically available at low cost across plans.

Intravenous Zoledronic Acid (Part B)

Zoledronic acid (Reclast) is administered as an IV infusion. As a physician-administered drug, zoledronic acid is covered under Medicare Part B. Beneficiary cost-sharing is the standard Part B coinsurance after the deductible. Refer to current FDA prescribing information for dosing parameters.

Denosumab (Part B)

Denosumab (Prolia) is a RANK ligand inhibitor administered as a subcutaneous injection on a recurring schedule. As a physician-administered drug, denosumab is covered under Medicare Part B with standard coinsurance after the deductible. Refer to current FDA prescribing information for dosing interval and route.

Romosozumab (Part B)

Romosozumab (Evenity) is a sclerostin inhibitor administered as a subcutaneous injection on a time-limited course. As a physician-administered drug, romosozumab is covered under Medicare Part B with standard coinsurance after the deductible. Romosozumab is typically reserved for postmenopausal women at high fracture risk. Refer to current FDA prescribing information for the approved dosing regimen.

Anabolic Therapy (Part D)

Teriparatide (Forteo) and abaloparatide (Tymlos) are PTH analog anabolic therapies administered as daily self-injected subcutaneous injections. As self-administered drugs, these are covered under Medicare Part D for beneficiaries enrolled in Part D plans. Cost-sharing varies by plan formulary tier; refer to current FDA prescribing information for treatment duration limits.

Estrogen and SERMs (Part D)

Estrogen (when used for osteoporosis prevention/treatment) and selective estrogen receptor modulators (raloxifene/Evista) are covered under Medicare Part D. Estrogen use specifically for osteoporosis is now uncommon given alternative options.

Drug Therapy Monitoring BMM

After osteoporosis drug therapy initiation, monitoring BMM is typically performed at clinician-determined intervals to assess response, often more frequently early in therapy and at longer intervals once response is established. The drug therapy monitoring BMM is covered under NCD 150.3 Category 5 (monitoring FDA-approved osteoporosis drug therapy).

Bone Mass Measurement Service Codes

HCPCS 77080 DXA Axial Skeleton

HCPCS 77080 represents the standard DXA scan of the axial skeleton (hip and spine). 77080 is the most commonly used BMM code in Medicare. The Medicare-approved amount varies by geographic locality; the Palmetto GBA fee schedule reflects Georgia-specific pricing.

HCPCS 77081 DXA Appendicular Skeleton

HCPCS 77081 represents DXA scan of the appendicular (peripheral) skeleton, typically the forearm. 77081 is used less commonly than 77080.

HCPCS 76977 Ultrasound Bone Density

HCPCS 76977 represents quantitative ultrasound bone density measurement at a peripheral site (typically the heel). 76977 is used in some screening contexts but is less common than DXA for definitive diagnosis.

HCPCS 77078 Quantitative CT

HCPCS 77078 represents quantitative CT bone density measurement. 77078 is used in specific clinical contexts but represents a small share of Medicare BMM volume.

For current code descriptors and any annual code updates, consult the CMS HCPCS file or the Palmetto GBA Local Coverage publications.

Documentation Requirements

Ordering Provider Documentation

The ordering provider must document:

• Qualifying NCD 150.3 category
• Frequency compliance (or justification for more-frequent BMM)
• Clinical indication for BMM
• Appropriate ICD-10 coding
• Order signature and date

Imaging Facility Documentation

The performing imaging facility documents:

• Patient identification
• Scan parameters
• Quality control compliance
• T-score and Z-score results
• Interpretation report
• Comparison to prior studies (if applicable)

Claim Documentation

The Medicare claim must:

• Use the appropriate HCPCS code
• Use the appropriate ICD-10 diagnosis code
• Identify the ordering provider
• Reflect assignment-accepting payment terms

Worked Examples

Example 1: Postmenopausal Woman in Marietta

Mrs. Johnson, a postmenopausal Marietta resident with a family history of osteoporosis (her mother had a hip fracture in her early seventies), attends her Annual Wellness Visit at a Wellstar primary care office. The provider notes she has not had a BMM and recommends osteoporosis screening.

Order: The provider orders HCPCS 77080 DXA axial skeleton with ICD-10 Z13.820 (Encounter for screening for osteoporosis) at the Wellstar imaging center. Mrs. Johnson schedules the DXA scan within a couple of weeks.

Coverage: The DXA is covered under NCD 150.3 Category 1 (estrogen-deficient postmenopausal woman) and aligns with USPSTF Grade B. Cost-sharing is waived under ACA Section 4104. Mrs. Johnson owes nothing for the DXA.

Results: DXA returns showing bone density in the osteopenia range. FRAX calculation suggests an elevated 10-year major osteoporotic fracture risk. The provider initiates oral alendronate (covered under Mrs. Johnson's Part D plan at low generic copay) and recommends weight-bearing exercise, adequate calcium and vitamin D intake, and follow-up DXA in two years.

Example 2: Glucocorticoid-Treated Patient Monitoring

Mr. Davis, an Atlanta resident with rheumatoid arthritis, has been on prednisone managed by his rheumatologist at Emory Bone Health. The rheumatologist orders a baseline BMM to assess glucocorticoid-induced osteoporosis risk.

Order: HCPCS 77080 DXA axial skeleton with ICD-10 M81.0 (Age-related osteoporosis without current pathological fracture) and Z79.52 (Long-term [current] use of systemic steroids).

Coverage: The DXA is covered under NCD 150.3 Category 3 (long-term glucocorticoid therapy). Because Mr. Davis is male and does not align with USPSTF Grade B (which applies to women), standard Part B cost-sharing applies (20 percent coinsurance after deductible). Mr. Davis's Medicare Supplement plan covers the coinsurance.

Results: DXA returns showing bone density in the osteoporosis range. The rheumatologist initiates IV zoledronic acid (under Part B) and continues calcium/vitamin D supplementation. Annual follow-up DXA is scheduled to monitor response to therapy.

Example 3: Drug Therapy Effectiveness Monitoring Follow-Up

Mrs. Brown, an Athens resident, was diagnosed with osteoporosis two years ago and initiated on oral alendronate. Her primary care provider orders a follow-up DXA to assess therapy response.

Order: HCPCS 77080 DXA axial skeleton with ICD-10 M81.0 (osteoporosis) and Z79.83 (Long-term [current] use of bisphosphonates).

Coverage: The DXA is covered under NCD 150.3 Category 5 (monitoring FDA-approved osteoporosis drug therapy). Cost-sharing under ACA Section 4104 applies because Mrs. Brown aligns with USPSTF Grade B. She owes nothing.

Results: DXA returns showing improvement in bone density values from baseline. The provider continues alendronate with planned re-evaluation for drug holiday consideration after the conventional treatment interval.

Example 4: Vertebral Fracture Workup

Ms. Williams, a Macon resident in her early seventies, presents with new back pain. X-ray reveals a T12 vertebral compression fracture without trauma. The primary care provider orders a DXA to characterize underlying osteoporosis.

Order: HCPCS 77080 DXA axial skeleton with ICD-10 M80.08 (Age-related osteoporosis with current pathological fracture, vertebra(e)).

Coverage: The DXA is covered under NCD 150.3 Category 2 (vertebral abnormality demonstrated by X-ray). Cost-sharing under ACA Section 4104 applies (USPSTF Grade B aligned). She owes nothing.

Results: DXA returns showing severe established osteoporosis given the existing fracture. The provider initiates IV zoledronic acid (Part B) and refers to physical therapy for fracture management.

Example 5: Primary Hyperparathyroidism BMM

Mr. Garcia, an Augusta resident, was recently diagnosed with primary hyperparathyroidism (elevated PTH, mildly elevated calcium) by his endocrinologist at Augusta University. The endocrinologist orders BMM to assess bone density impact.

Order: HCPCS 77080 DXA axial skeleton with ICD-10 E21.0 (Primary hyperparathyroidism).

Coverage: The DXA is covered under NCD 150.3 Category 4 (primary hyperparathyroidism). Standard Part B cost-sharing applies (USPSTF Grade B does not apply). Mr. Garcia's Medicare Supplement plan covers the 20 percent coinsurance.

Results: DXA shows mild osteopenia. The endocrinologist considers the BMM results among the criteria for parathyroidectomy and recommends surgical consultation given the bone density findings.

Example 6: Rural Georgia DXA Access Challenge

Mrs. Anderson, a resident of Sylvester in Worth County (rural southwest Georgia), needs an osteoporosis screening DXA. Her local FQHC primary care provider orders the DXA but notes that the nearest DXA imaging facility is in Albany at Phoebe Putney.

Order: HCPCS 77080 DXA axial skeleton with ICD-10 Z13.820 ordered through the FQHC, with imaging at Phoebe Putney Imaging.

Coverage: The DXA is covered under NCD 150.3 Category 1 (postmenopausal woman) and aligns with USPSTF Grade B. Cost-sharing is waived under ACA Section 4104.

Access Considerations: Mrs. Anderson coordinates transportation through a family member for the Albany DXA appointment. The travel is manageable but represents a typical rural Georgia access challenge. Some Georgia health systems offer mobile DXA services to rural counties to mitigate access barriers, though availability varies.

Results: DXA shows bone density at the osteopenia-osteoporosis boundary. FRAX-adjusted 10-year risk warrants treatment consideration. The FQHC primary care provider initiates oral alendronate (Part D coverage) and arranges follow-up DXA in two years.

Major Georgia Bone Health Programs

Emory Bone Health Program

Emory Bone Health Program (Atlanta) provides comprehensive osteoporosis evaluation and management at the academic medical center. Services include:

• DXA imaging at multiple Emory locations
• Endocrinology bone health consultations
• Rheumatology consultations for glucocorticoid-related bone health
• Drug therapy management
• FRAX risk assessment
• Bone health research participation

Wellstar Bone Health

Wellstar Bone Health provides bone health services across the Wellstar Health System's metropolitan Atlanta and north Georgia hospitals. Services include DXA imaging, endocrinology, and primary care-based bone health management.

Piedmont Bone Health

Piedmont Healthcare provides bone health services through Piedmont Atlanta and system hospitals. DXA imaging is available at multiple Piedmont locations.

Northside Hospital Bone Health

Northside Hospital provides bone health services through its women's health and endocrinology programs. DXA imaging is available at multiple Northside locations.

Augusta University Bone Health

Augusta University Medical Center provides academic bone health care for east Georgia. The Augusta University Endocrinology Division includes specialists in metabolic bone disease.

Other Georgia Bone Health Resources

Additional resources include:

• Phoebe Putney Imaging (Albany, southwest Georgia)
• Memorial Health Imaging (Savannah, coastal Georgia)
• Houston Healthcare (Warner Robins)
• Floyd Healthcare (Rome)
• Local hospital-based DXA imaging in regional medical centers
• Outpatient imaging center DXA services
• Some primary care offices with in-office DXA

DXA Facility Standards

FDA Equipment Requirements

Section 1861(rr) requires that BMM be performed with FDA-approved or FDA-cleared equipment. All DXA machines used for Medicare-covered BMM must meet FDA standards.

ISCD Standards

The International Society for Clinical Densitometry (ISCD) provides standards for:

• DXA scan acquisition
• Result reporting
• T-score and Z-score interpretation
• Quality control
• Operator training and certification

Many Georgia DXA facilities follow ISCD standards and may have ISCD-certified technologists and interpreting physicians.

Quality Control

DXA facilities perform daily and weekly quality control scans of phantoms to ensure accuracy and precision. Quality control documentation supports Medicare claim integrity.

Provider Best Practices

1. Systematic AWV implementation: Use AWVs as the recurring touchpoint for BMM management for at-risk beneficiaries
2. Two-year frequency tracking: EMR-based tracking of last BMM date and next eligible screening
3. Risk factor documentation: Document qualifying NCD 150.3 category clearly
4. USPSTF alignment awareness: Understand which BMM orders qualify for zero cost-sharing vs standard cost-sharing
5. Coordination with women's health: Integrate BMM into postmenopausal women's health care
6. Glucocorticoid awareness: Order BMM for patients initiating long-term steroids
7. FRAX integration: Use FRAX to translate BMM results into individualized treatment recommendations
8. Coding accuracy: Use appropriate ICD-10 codes for screening vs diagnostic vs monitoring contexts
9. Drug therapy initiation pathway: Coordinate BMM results with osteoporosis drug therapy initiation
10. Monitoring BMM workflow: Schedule follow-up BMM for therapy response monitoring
11. Specialty referral coordination: Refer complex cases to endocrinology or rheumatology
12. Lifestyle counseling: Address calcium, vitamin D, exercise, smoking, alcohol
13. Fall prevention coordination: Integrate BMM with broader fall prevention strategies
14. Beneficiary education: Explain bone health, BMM results, and treatment options

Common Issues and Resolutions

1. Beneficiary charged cost-sharing for screening BMM in USPSTF Grade B aligned woman: Often a coding error. Resolution: claim correction with appropriate screening ICD-10.
2. BMM ordered before two-year eligibility: Frequency violation results in denial. Resolution: verify last BMM date; if clinically necessary for monitoring, order under more-frequent coverage with appropriate documentation.
3. Provider unaware of NCD 150.3 categories: Some providers miss the breadth of qualifying categories. Resolution: provider education on the Category 1-5 framework.
4. Confusion about cost-sharing for non-USPSTF aligned BMM: Resolution: clearly counsel beneficiaries about cost-sharing for indications not aligned with USPSTF Grade B.
5. Inconsistent T-score reporting: Some facilities report inconsistent or non-standard T-scores. Resolution: use ISCD-aligned facilities for consistent results.
6. Missing FRAX integration: Resolution: integrate FRAX assessment into provider workflow for risk-stratified treatment decisions.
7. Rural beneficiary DXA access barriers: Resolution: refer to regional facilities, use mobile DXA services where available.
8. Provider missing glucocorticoid-induced osteoporosis monitoring: Resolution: implement EMR alerts for patients on long-term steroids.
9. Failure to initiate therapy after osteoporosis diagnosis: Resolution: implement workflow to ensure abnormal BMM leads to treatment consideration.
10. Drug therapy monitoring BMM not scheduled: Resolution: implement follow-up BMM scheduling at therapy initiation.
11. Confusion between Part B and Part D osteoporosis drugs: Resolution: clarify coverage pathway for each drug.
12. EMR doesn't flag BMM eligibility: Resolution: implement EMR reminder systems.
13. Beneficiary doesn't understand DXA process: Resolution: clear pre-test patient education.
14. Comparison to prior studies missing: Resolution: ensure DXA facility has access to prior studies for proper comparison.

A few more common questions:

What is DXA? Dual-energy X-ray absorptiometry (DXA) is the gold-standard technology for BMM. DXA uses low-dose X-ray to measure bone mineral density at the hip, spine, or other sites. DXA results are reported as T-scores and Z-scores. DXA is non-invasive and painless.

What is a T-score versus a Z-score? A T-score is a measure of bone density expressed as standard deviations from a young adult reference population (used to categorize normal bone, osteopenia, and osteoporosis per WHO thresholds). A Z-score compares bone density to age-matched reference populations and is particularly useful for premenopausal women, men under 50, and pediatric populations.

What is FRAX? FRAX (Fracture Risk Assessment Tool) integrates DXA results with clinical risk factors to estimate 10-year probability of major osteoporotic fracture and hip fracture. FRAX informs individualized treatment recommendations.

What osteoporosis medications does Medicare cover? Medicare covers osteoporosis medications through Part B (physician-administered) and Part D (self-administered). Part B coverage includes intravenous zoledronic acid, denosumab (Prolia), and romosozumab (Evenity). Part D coverage includes oral bisphosphonates (alendronate, risedronate, ibandronate), teriparatide (Forteo), abaloparatide (Tymlos), estrogen, and SERMs.

What is the difference between osteopenia and osteoporosis? Osteopenia is low bone mass (bone density below normal but not severely low). Osteoporosis is more severe bone loss (significantly below normal, with elevated fracture risk). Per WHO criteria, the categories are distinguished by progressively lower T-score bands.

What if I have a fragility fracture? Fragility fractures (fractures from minor trauma like a fall from standing height) suggest osteoporosis. Your provider should order BMM under NCD 150.3 Category 2 (vertebral abnormality) or as part of broader osteoporosis workup. Established osteoporosis (osteoporotic-range bone density plus a fragility fracture) typically warrants pharmacologic therapy.

What is the role of calcium and vitamin D? Adequate calcium and vitamin D are foundational for bone health alongside any pharmacologic therapy. Refer to current Bone Health and Osteoporosis Foundation and USPSTF guidance for recommended intake levels for older adults; supplementation is particularly relevant in northern latitudes during winter months when sunlight-derived vitamin D synthesis is limited.

Is there a drug holiday for bisphosphonates? For long-term bisphosphonate users, clinicians may consider a drug holiday (temporarily stopping the bisphosphonate to balance benefits against rare adverse effects such as atypical femoral fractures and osteonecrosis of the jaw). Drug holiday decisions are individualized based on BMM results, fracture risk, and treatment response.

How is denosumab different? Denosumab (Prolia) is a RANK ligand inhibitor administered on a recurring subcutaneous schedule. Unlike bisphosphonates, denosumab requires continued use to maintain bone density benefits; discontinuation without transition to another therapy can lead to rebound bone loss and vertebral fracture risk. Denosumab is covered under Medicare Part B.

How do I find Medicare-covered DXA imaging in my area? Contact your primary care provider for referrals, call 1-800-MEDICARE, use Medicare.gov's care-finder tool, contact local hospitals or imaging centers, or reach out to GeorgiaCares SHIP.

Will Medicare Advantage cover the same BMM benefits? Yes. Medicare Advantage plans must cover at least the same BMM benefits as Original Medicare. Cost-sharing structure for in-network providers should be similar (zero cost-sharing for USPSTF Grade B aligned BMM, standard plan cost-sharing for other indications).

What if my screening DXA shows osteopenia? Osteopenia warrants individualized risk assessment. Your provider may use FRAX to estimate fracture risk and discuss treatment options. Some patients with osteopenia warrant pharmacologic therapy; others may continue lifestyle interventions and repeat BMM in two years.

Can I get BMM more often than every two years? Yes, when clinically indicated. NCD 150.3 allows more-frequent BMM for monitoring response to FDA-approved osteoporosis drug therapy, monitoring high-dose glucocorticoids, and other documented clinical situations. The ordering provider documents the clinical necessity.